title: Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).
authors.forename: Reinhard
authors.initials: R
authors.lastname: Zenhäusern
authors.forename: Mathew
authors.initials: M
authors.lastname: Simcock
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
authors.forename: Urs
authors.initials: U
authors.lastname: Hess
authors.forename: Mario
authors.initials: M
authors.lastname: Bargetzi
authors.forename: Andreas
authors.initials: A
authors.lastname: Tobler
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use*; D017338:Cladribine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008297:Male; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D017338:Cladribine; D000069283:Rituximab